[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601856":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":175,"collaborators":179,"id":182,"slug":183,"hasResults":184,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":184,"sex":190,"minAge":191,"maxAge":192,"enrollmentInfo":193,"targetDuration":26,"studyType":196,"phases":197,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":213},{"fullName":5,"class":6},"University Hospitals Cleveland Medical Center","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Medical Management with Endovascular Thrombectomy","EXPERIMENTAL","Medical management with endovascular thrombectomy (EVT) - EVT will be provided in addition to medical management and is a procedure to remove a thrombus in one of the brain arteries that is obstructing the blood flow. Removing this occlusion results in restoration of blood flow to ischemic brain tissue and salvage of the parts that are still viable, which is expected to improve functional outcomes. Endovascular thrombectomy procedure will be performed using stent retrievers, aspiration devices or combination approach at the discretion of the treating physician, using devices approved by the local regulatory authority. For patients treated in the United States of America, only US Food and Drug Administration-approved neurothrombectomy devices can be used.",[13,14],"Device: Endovascular Thrombectomy","Other: Medical Management",{"label":16,"type":17,"description":18,"interventionNames":19},"Medical Management without Endovascular Thrombectomy","ACTIVE_COMPARATOR","Medical management without endovascular thrombectomy comprises various measures to prevent further deterioration, enhance patients' outcomes and prevent occurrence of a secondary stroke in short and long term. This includes 1) evidence-based practices for blood pressure management 2) Neurocritical care monitoring with appropriate osmotic therapy and neurosurgical interventions such as hemicraniectomy for management of cerebral edema that occurs due to infracted brain tissue based on local institutional protocol, 3) stroke etiology identification by requisite neurology , cardiology, immunology evaluations and 4) short and long-term strategies for secondary stroke prevention, including anticoagulation, antiplatelet therapy, medical optimization and modification of stroke risk factors such as hypertension, hyperlipidemia, diabetes and other potential comorbidities.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Endovascular Thrombectomy","EVT will be provided in addition to medical management and is a procedure to remove a thrombus in one of the brain arteries that is obstructing the blood flow and is responsible for the occurrence of stroke. Removing this occlusion results in restoration of blood flow to ischemic brain tissue and salvages the parts that are still viable, which is expected to improve functional outcomes. Endovascular thrombectomy procedure will be performed using stent retrievers, aspiration devices or combination approach at the discretion of the treating physician, using devices approved by the local regulatory authority. For patients treated in the United States of America, only US Food and Drug Administration-approved neurothrombectomy devices can be used.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Medical Management","Medical management comprises various measures to prevent further deterioration, enhance patients' outcomes and prevent occurrence of a secondary stroke in short and long term. This includes 1) evidence-based practices for blood pressure management 2) Neurocritical care monitoring with appropriate osmotic therapy and neurosurgical interventions such as hemicraniectomy for management of cerebral edema that occurs due to infracted brain tissue based on local institutional protocol, 3) stroke etiology identification by requisite neurology , cardiology, immunology evaluations and 4) short and long-term strategies for secondary stroke prevention, including anticoagulation, antiplatelet therapy, medical optimization and modification of stroke risk factors such as hypertension, hyperlipidemia, diabetes and other potential comorbidities.",[9,16],[32],{"name":33,"affiliation":34,"role":35},"Amrou Sarraj, MD","University Hospitals","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Kate Rownd, MED","CONTACT","216-286-6458","Kathryn.Rownd@UHhospitals.org",{"name":43,"role":39,"phone":26,"phoneExt":26,"email":44},"Deep Pujara, MBBS, MPH, MS","Deep.Pujara@UHHospitals.org",[46,70,90,110,131,152],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"University of Chicago","RECRUITING","Chicago","Illinois","60637","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-87.65005,41.85003,{"lat":58,"lon":57},[61,65,68],{"name":62,"role":39,"phone":63,"phoneExt":26,"email":64},"Khalid Trad, MD","708-886-0785","khalid.trad@bsd.uchicago.edu",{"name":66,"role":39,"phone":26,"phoneExt":26,"email":67},"Erin King, PhD, OTR\u002FL","erinking1@bsd.uchicago.edu",{"name":69,"role":35,"phone":26,"phoneExt":26,"email":26},"Tareq Kass-Hout, MD",{"facility":71,"status":48,"city":72,"state":73,"zip":74,"country":52,"countryCode":53,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"The University of Kansas Health System","Kansas City","Kansas","66103",{"type":55,"coordinates":76},[77,78],-94.62746,39.11417,{"lat":78,"lon":77},[81,85,88],{"name":82,"role":39,"phone":83,"phoneExt":26,"email":84},"Anika Zainab","913-574-4186","azainab@kumc.edu",{"name":86,"role":39,"phone":26,"phoneExt":26,"email":87},"Margaret Houghton","mhoughton3@kumc.edu",{"name":89,"role":35,"phone":26,"phoneExt":26,"email":26},"Michael G Abraham, MD, FAHA, FSVIN",{"facility":91,"status":48,"city":92,"state":93,"zip":94,"country":52,"countryCode":53,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"Washington University School of Medicine","St Louis","Missouri","61611",{"type":55,"coordinates":96},[97,98],-90.19789,38.62727,{"lat":98,"lon":97},[101,105,108],{"name":102,"role":39,"phone":103,"phoneExt":26,"email":104},"Alyssa Hiserote, MSN, RN","314-369-6880","calyssa@wustl.edu",{"name":106,"role":39,"phone":103,"phoneExt":26,"email":107},"Jennifer Babka, PhD, RN","babkaj@wustl.edu",{"name":109,"role":35,"phone":26,"phoneExt":26,"email":26},"Brendan Eby, MD",{"facility":111,"status":48,"city":112,"state":113,"zip":114,"country":52,"countryCode":53,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Rhode Island Hospital","Providence","Rhode Island","02903",{"type":55,"coordinates":116},[117,118],-71.41283,41.82399,{"lat":118,"lon":117},[121,125,129],{"name":122,"role":39,"phone":123,"phoneExt":26,"email":124},"Wendy Smith, BS, RTRCV, CCRP","401-444-4233","wsmith@brownhealth.org",{"name":126,"role":39,"phone":127,"phoneExt":26,"email":128},"Barbara Marcotte, RTRCT","401-444-8055","mbarcotte@brownhealth.org",{"name":130,"role":35,"phone":26,"phoneExt":26,"email":26},"Dylan Wolman, MD",{"facility":132,"status":48,"city":133,"state":134,"zip":135,"country":52,"countryCode":53,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Baylor University Medical Center","Dallas","Texas","75246",{"type":55,"coordinates":137},[138,139],-96.80667,32.78306,{"lat":139,"lon":138},[142,146,150],{"name":143,"role":39,"phone":144,"phoneExt":26,"email":145},"Mariana Hurutado-Rodriguez","214-346-1330","Mariana.Hurutado@BSWHealth.org",{"name":147,"role":39,"phone":148,"phoneExt":26,"email":149},"Daniela Gonzalez","214-820-6243","Daniela.gonzalez1@bswhealth.org",{"name":151,"role":35,"phone":26,"phoneExt":26,"email":26},"Osman Mir, MD",{"facility":153,"status":48,"city":154,"state":155,"zip":156,"country":52,"countryCode":53,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"West Virginia University","Morgantown","West Virginia","26506",{"type":55,"coordinates":158},[159,160],-79.9559,39.62953,{"lat":160,"lon":159},[163,168,173],{"name":164,"role":39,"phone":165,"phoneExt":166,"email":167},"Jennifer Domico, RN, CCRP","304-293-7012","37012","Jennifer.domico@WVUmedicine.org",{"name":169,"role":39,"phone":170,"phoneExt":171,"email":172},"Mohammed Elshahat, MD","304-293-1443","31443","mohammed.elshahat@hsc.wvu.edu",{"name":174,"role":35,"phone":26,"phoneExt":26,"email":26},"Sohyun Boo, MD",{"type":176,"investigatorFullName":177,"investigatorTitle":178,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"SPONSOR_INVESTIGATOR","Amrou Sarraj","Professor of Neurology at the CWRU School of Medicine",[180],{"name":181,"class":6},"Patient-Centered Outcomes Research Institute","100601856","medical-management-with-endovascular-thrombectomy-versus-medical-management-alone-in-patients-presenting-beyond-24-hours-of-last-known-well-100601856",false,"NCT07115940","Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well","Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well - SELECT LATE Trial","SELECT LATE","Inclusion Criteria:\n\nGeneral Inclusion Criteria:\n\n* Adults (18-85\\* years) with the final diagnosis of an acute ischemic stroke$\n* NIHSS ≥ 6\n* Time from last-known-well to randomization \\>24 - 72 hours\n* Pre-stroke modified Rankin Scale score of 0-1\n* Eligible for thrombectomy and medical management\n* Signed Informed Consent obtained\n* Subject willing to comply with the protocol follow-up requirements\n* Anticipated life expectancy of at least 3 months \\*Inclusive of both 18 and 85 years of age (i.e. up to 86th birthdate). $Subacute presentation - In-hospital stroke admissions with fluctuating clinical symptoms for patients who presented to EVT centers within 24 hours of when they were last known well will not be eligible for the trial.\n\nGeneral Exclusion Criteria\n\n* Current participation in another investigational interventional drug or device study.\n* Baseline Platelet count \\\u003C100,000\u002Fμl\n\nImaging Inclusion Criteria\n\n* Proven large vessel occlusion in ICA or MCA-M1 occlusion (carotid occlusions can be cervical or intracranial, with or without tandem MCA lesions), as determined by MR Angiography (MRA) or CT Angiography (CTA)\n* CT ASPECTS 3-10\n* CT Perfusion ischemic core (rCBF \\\u003C30%)# volume ≤150 ml OR MR Diffusion ischemic core (ADC \\\u003C620x10-6 mm2\u002Fs)# volume ≤150ml #If the perfusion software at enrollment center uses another threshold\u002Fmeasure to define ischemic core, please use that measure to assess ischemic core criteria.\n\nImaging Exclusion Criteria\n\n* Evidence of intracranial tumor (except small meningioma \\\u003C3cm without signs of edema or inflammation), acute intracranial hemorrhage, or arteriovenous malformation\n* Significant mass effect, defined as midline shift (\\>3mm) using foramen of monroe (anterior margin of third ventricle) as the marker for midline instead of septum pellucidum AND\u002FOR Effacement of sulci in contralateral hemisphere\n* Evidence of internal carotid artery dissection that is flow limiting or aortic dissection\n* Intracranial stent implanted in the same vascular territory that precludes the safe deployment\u002Fremoval of the neurothrombectomy device\n* Acute symptomatic arterial occlusions in more than one vascular territory confirmed on CTA\u002FMRA (e.g., bilateral MCA occlusions, or an MCA and a basilar artery occlusion).\n* Any signs of established infarct, demarcating hypodensity and area of cerebral edema on non-contrast CT\n* CT ASPECTS 0-2\n* CT Perfusion ischemic core (rCBF \\\u003C30%)# volume \\>150 ml OR MR Diffusion ischemic core (ADC \\\u003C620x10-6 mm2\u002Fs)# volume \\>150ml #If the perfusion software at enrollment center uses another threshold\u002Fmeasure to define ischemic core, please use that measure to assess ischemic core criteria.","ALL","18 Years","85 Years",{"count":194,"type":195},408,"ESTIMATED","INTERVENTIONAL",[198],"NA","SELECT LATE trial aims to evaluate if addition of endovascular thrombectomy to medical management in patients presenting with acute ischemic stroke and a proximal large vessel occlusion in the anterior circulation between 24 and 72 hours of stroke onset results in achieving better functional outcomes (measured using modified Rankin Scale Scores) at 90-day follow-up (± 15 days).",[201],"Acute Ischemic Stroke",[23,203],"Mechanical Thrombectomy","2026-07-01",{"date":206,"type":207},"2026-07-06","ACTUAL",{"date":209,"type":207},"2026-04-13",{"date":211,"type":195},"2029-12-01",{"name":177,"class":6},6]